Rituximab-Induced Acute Severe Thrombocytopenia: A Case Series in Patients With Mantle Cell Lymphoma
Rituximab-Induced Acute Severe Thrombocytopenia: A Case Series in Patients With Mantle Cell Lymphoma
复制标题
DOI：
10.1016/j.clml.2013.04.013
复制
发表时间：
2013-10-01
影响因子：
2.7
通讯作者：
Lister, John
中科院分区：
文献类型：
--
作者：
Sadashiv, Santhosh K.;Rao, Rohit;Lister, John
套细胞淋巴瘤（MCL）是B细胞非霍奇金淋巴瘤的一种形式，根据世界卫生组织的标准被分类为中间型。它主要影响五、六十岁的患者，是所有B细胞NHL中预后最差的。治疗包括积极的化疗方案和利妥昔单抗，目标是在符合条件的患者中实现完全缓解，然后进行自体干细胞移植。在NHL治疗中加入利妥昔单抗对总体反应和生存产生了显著影响。大多数耐受良好，利妥昔单抗毒性主要是输液相关的超敏反应。血细胞减少是血液学毒性，通常在输注利妥昔单抗后10-14天发生。
Mantle cell lymphoma (MCL) is a form on B cell non-Hodgkin's lymphoma and by World Health Organization criteria is sub-classified as intermediate type. Mostly affecting patients in their fifth or sixth decade, it carries the worst prognosis of all B cell NHL. Treatment involves aggressive chemotherapy regimen along with rituximab with a goal to achieve complete remission followed by autologous stem cell transplant in eligible patients. Addition of rituximab in the treatment of NHL has made a significant impact in overall response and survival. Mostly well tolerated, rituximab toxicities are mainly infusion related hypersensitivity reactions. Cytopenias are the described hematological toxicities and they usually occur 10–14 days following rituximab infusion.